Roundview Capital LLC Lowers Stock Holdings in Pfizer Inc. $PFE

Roundview Capital LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 15.0% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 24,888 shares of the biopharmaceutical company’s stock after selling 4,381 shares during the quarter. Roundview Capital LLC’s holdings in Pfizer were worth $603,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of PFE. Brighton Jones LLC lifted its stake in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC increased its holdings in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares during the last quarter. Courier Capital LLC increased its holdings in Pfizer by 3.2% in the 1st quarter. Courier Capital LLC now owns 53,033 shares of the biopharmaceutical company’s stock valued at $1,344,000 after acquiring an additional 1,666 shares during the last quarter. City Holding Co. increased its holdings in Pfizer by 6.9% in the 1st quarter. City Holding Co. now owns 36,224 shares of the biopharmaceutical company’s stock valued at $918,000 after acquiring an additional 2,352 shares during the last quarter. Finally, Farther Finance Advisors LLC increased its holdings in Pfizer by 44.1% in the 1st quarter. Farther Finance Advisors LLC now owns 85,290 shares of the biopharmaceutical company’s stock valued at $2,093,000 after acquiring an additional 26,095 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

PFE stock opened at $26.27 on Wednesday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a 50-day moving average price of $24.76 and a 200 day moving average price of $24.14. The stock has a market cap of $149.36 billion, a PE ratio of 13.97, a P/E/G ratio of 0.86 and a beta of 0.55.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same period in the previous year, the company earned $0.60 EPS. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on PFE shares. UBS Group reiterated a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Saturday, September 27th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Morgan Stanley boosted their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 6th. Finally, Citigroup boosted their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average target price of $28.41.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.